Switching to certain antidiabetic drugs linked to increased risk of major complications

July 18, 2018, British Medical Journal
Credit: CC0 Public Domain

For people with type 2 diabetes, switching to sulfonylurea drugs to control blood sugar levels is associated with an increased risk of complications compared with staying on the drug metformin, finds a study in The BMJ today.

As such, the researchers say that continuing metformin when introducing sulfonylureas is safer than switching.

Metformin is a "first-line" therapy (the first drug that will be tried) for patients with type 2 diabetes. But sulfonylureas are the most commonly prescribed "second line" treatment, and often used in combination with metformin.

The safety of sulfonylureas has been studied extensively. However, little is known about the specific risk of adding or switching to sulfonylureas compared with staying on metformin treatment alone.

So a research team, led by Professor Samy Suissa at McGill University in Canada, set out to assess whether adding or switching to sulfonylureas is associated with an increased risk of serious complications, compared with remaining on metformin alone in patients with type 2 diabetes.

They analysed data from the UK Clinical Practice Research Datalink for over 77,000 patients (average age 64 years) with type 2 diabetes who started metformin treatment between 1998 and 2013.

Patients who subsequently added or switched to a sulfonylurea were identified and matched to a similar patient who continued metformin alone.

Hospital records were then used to monitor admissions for (myocardial infarction) and ischaemic stroke, , death from any cause ("all cause mortality"), and dangerously low (severe hypoglycemia).

During an average follow-up period of just over a year, sulfonylurea use (switching and adding combined) was associated with an increased risk of heart attack (7.8 v 6.2 per 1000 person years), all cause mortality (27.3 v 21.5), and severe hypoglycaemia (5.5 v 0.7), compared with continuing metformin alone.

There was also a trend towards increased risks of ischaemic stroke (6.7 v 5.5 per 1000 person years) and cardiovascular death (9.4 v 8.1) with sulfonylurea use.

Compared with adding sulfonylureas to metformin treatment, switching to sulfonylureas was associated with a greater risk of heart attack and all cause mortality, but no differences were found for ischaemic stroke, cardiovascular death, or severe hypoglycaemia.

Findings remained similar after further analyses to test the strength of the results.

This is an observational study, so cannot establish cause and effect, and the researchers say they cannot rule out the possibility that some of the observed risk may be due to other unmeasured (confounding) factors. Nevertheless, they say their results are highly generalisable and the large sample size allowed the calculation of precise estimates.

As such, they conclude that sulfonylureas as second line drugs "are associated with an increased risk of myocardial infarction, all cause mortality, and severe hypoglycaemia, compared with remaining on metformin monotherapy."

Importantly, the associations with and all cause mortality "were driven by switching to sulfonylureas and not the addition of sulfonylureas," they add. "Thus, in line with current recommendations on the treatment of type 2 diabetes, continuing when introducing sulfonylureas is safer than switching."

In a linked editorial, US researchers Lucy D'Agostino McGowan and Christianne Roumie, say this new evidence helps to individualise decisions and minimise harm.

They point out that it is hard to define based on an observational study, as using different therapies may differ in ways that are unmeasured. However, they say this study "is well designed and the relationships appear strong and consistent."

Explore further: CVD risk similar for metformin + insulin or sulfonylureas

More information: Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study, The BMJ, www.bmj.com/content/362/bmj.k2693

Editorial: Sulfonylureas as second line treatment for type 2 diabetes, The BMJ, www.bmj.com/content/362/bmj.k3041

Related Stories

CVD risk similar for metformin + insulin or sulfonylureas

July 20, 2015
(HealthDay)—For patients with type 2 diabetes, the risk of myocardial infarction (MI) or stroke is similar for treatment with insulin or sulfonylureas in combination with metformin, according to a study published online ...

First-line metformin use for DM up; sulfonylurea use down

November 19, 2017
(HealthDay)—Among patients with type 2 diabetes initiating antidiabetes drugs (ADDs), first-line use of metformin has increased since 2005, while sulfonylureas have remained the most popular second-line agent, according ...

Sulfonylureas up cardio events versus metformin

November 7, 2012
(HealthDay)—Use of sulfonylureas for initial treatment of diabetes is associated with increased cardiovascular events and death compared with metformin, according to a study published in the Nov. 6 issue of the Annals of ...

Metformin linked to increased risk of acute dialysis in T2DM

August 23, 2016
(HealthDay)—For patients with type 2 diabetes, metformin is associated with about a 50 percent increase in the risk of acute dialysis compared to sulfonylureas, according to a study published online Aug. 18 in Diabetes, ...

Metformin use doesn't cut incidence of bladder cancer

February 11, 2014
(HealthDay)—For patients with type 2 diabetes, metformin use is not associated with a significantly reduced risk of bladder cancer, according to a study published online Feb. 4 in Diabetes Care.

Common diabetes drugs may carry risk, study suggests

September 26, 2013
(HealthDay)—Diabetes patients who take drugs called sulfonylureas as an initial therapy have a higher risk of death than those who take the diabetes drug metformin, a new study says.

Recommended for you

Using mushrooms as a prebiotic may help improve glucose regulation

August 16, 2018
Eating white button mushrooms can create subtle shifts in the microbial community in the gut, which could improve the regulation of glucose in the liver, according to a team of researchers. They also suggest that better understanding ...

Cardiovascular disease related to type 2 diabetes can be reduced significantly

August 16, 2018
Properly composed treatment and refraining from cigarette consumption can significantly reduce the risk of cardiovascular disease resulting from type 2 diabetes, according to a study published in the New England Journal of ...

Blood test may identify gestational diabetes risk in first trimester

August 16, 2018
A blood test conducted as early as the 10th week of pregnancy may help identify women at risk for gestational diabetes, a pregnancy-related condition that poses potentially serious health risks for mothers and infants, according ...

Weight gain after smoking cessation linked to increased short-term diabetes risk

August 15, 2018
People who gain weight after they quit smoking may face a temporary increase in the risk of developing type 2 diabetes, with the risk directly proportional to the weight gain, according to a new study from Harvard T.H. Chan ...

Evening preference, lack of sleep associated with higher BMI in people with prediabetes

August 15, 2018
People with prediabetes who go to bed later, eat meals later and are more active and alert later in the day—those who have an "evening preference"—have higher body mass indices compared with people with prediabetes who ...

Healthy fat cells uncouple obesity from diabetes

August 14, 2018
About 422 million people around the world, including more than 30 million Americans, have diabetes. Approximately ninety percent of them have type 2 diabetes. People with this condition cannot effectively use insulin, a hormone ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.